MedTrace Logo

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

NCT00097903 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-03-12

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.

Conditions

  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Karenitecin (BNP1350)

Phase 1 study,dose-escalation design

Sponsors & Collaborators

  • Crown Bioscience

    collaborator INDUSTRY

  • BioNumerik Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2011-10-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097903 on ClinicalTrials.gov